PL3995507T3 - Il-15 i domena sushi il-15ralfa oparte na moldulokinach - Google Patents

Il-15 i domena sushi il-15ralfa oparte na moldulokinach

Info

Publication number
PL3995507T3
PL3995507T3 PL21200870.0T PL21200870T PL3995507T3 PL 3995507 T3 PL3995507 T3 PL 3995507T3 PL 21200870 T PL21200870 T PL 21200870T PL 3995507 T3 PL3995507 T3 PL 3995507T3
Authority
PL
Poland
Prior art keywords
modulokines
domain based
sushi domain
15ralpha sushi
15ralpha
Prior art date
Application number
PL21200870.0T
Other languages
English (en)
Inventor
Alain GEY
Eric Tartour
David Bechard
Original Assignee
Cytune Pharma
Université Paris Cité
Assistance Publique Hôpitaux De Paris
INSERM (Institut National de la Santé et de la Recherche Médicale)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48953308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3995507(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytune Pharma, Université Paris Cité, Assistance Publique Hôpitaux De Paris, INSERM (Institut National de la Santé et de la Recherche Médicale) filed Critical Cytune Pharma
Publication of PL3995507T3 publication Critical patent/PL3995507T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Image Processing (AREA)
PL21200870.0T 2013-08-08 2014-08-08 Il-15 i domena sushi il-15ralfa oparte na moldulokinach PL3995507T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13003963 2013-08-08

Publications (1)

Publication Number Publication Date
PL3995507T3 true PL3995507T3 (pl) 2024-03-04

Family

ID=48953308

Family Applications (3)

Application Number Title Priority Date Filing Date
PL18177685T PL3444271T3 (pl) 2013-08-08 2014-08-08 Modulokiny oparte na il-15 i domenie sushi il-15ralfa
PL14761280T PL3030575T3 (pl) 2013-08-08 2014-08-08 Modulokiny oparte na il-15 i domenie sushi il-15r-alfa
PL21200870.0T PL3995507T3 (pl) 2013-08-08 2014-08-08 Il-15 i domena sushi il-15ralfa oparte na moldulokinach

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL18177685T PL3444271T3 (pl) 2013-08-08 2014-08-08 Modulokiny oparte na il-15 i domenie sushi il-15ralfa
PL14761280T PL3030575T3 (pl) 2013-08-08 2014-08-08 Modulokiny oparte na il-15 i domenie sushi il-15r-alfa

Country Status (18)

Country Link
US (2) US11273204B2 (pl)
EP (4) EP3995507B1 (pl)
JP (2) JP6649254B2 (pl)
KR (2) KR102564207B1 (pl)
CN (1) CN105612175B (pl)
AU (1) AU2014304931B2 (pl)
BR (1) BR112016002614B1 (pl)
CA (1) CA2919725C (pl)
DK (2) DK3444271T3 (pl)
EA (1) EA031080B1 (pl)
ES (3) ES2963591T3 (pl)
HR (3) HRP20231437T1 (pl)
HU (2) HUE064280T2 (pl)
MX (1) MX2016001555A (pl)
PL (3) PL3444271T3 (pl)
PT (2) PT3444271T (pl)
SI (2) SI3030575T1 (pl)
WO (1) WO2015018528A1 (pl)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI531652B (zh) 2005-12-02 2016-05-01 美國紐約大學西奈山醫學院 表現非原生表面蛋白質之嵌合病毒及其用途
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EP3620473A1 (en) 2013-01-14 2020-03-11 Xencor, Inc. Novel heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
JP6596411B2 (ja) 2013-03-14 2019-10-23 アイカーン スクール オブ メディシン アット マウント サイナイ ニューカッスル病ウイルス及びその使用
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
AU2014232416B2 (en) 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
CA2909576C (en) * 2013-04-19 2023-07-18 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
KR20230097209A (ko) 2014-03-12 2023-06-30 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
CN111410691B (zh) 2014-03-28 2024-02-13 Xencor公司 结合至cd38和cd3的双特异性抗体
WO2016086196A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
LT3223845T (lt) 2014-11-26 2021-08-25 Xencor, Inc. Heterodimeriniai antikūnai, kurie suriša cd3 ir cd20
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US20180155439A1 (en) * 2015-06-10 2018-06-07 Emory University Compositions and Conjugates Comprising an Interleukin and Polypeptides That Specifically Bind TGF-beta
JP6800219B2 (ja) 2015-09-16 2020-12-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 特異的なインターロイキン−１５（ｉｌ−１５）アンタゴニストポリペプチド並びに炎症疾患及び自己免疫疾患の処置のためのその使用
AU2016329126B2 (en) 2015-10-02 2023-04-13 F. Hoffmann-La Roche Ag Bispecific antibodies specific for PD1 and TIM3
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
WO2017134301A1 (en) * 2016-02-05 2017-08-10 Orionis Biosciences Nv Clec9a binding agents
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
ES2831852T3 (es) * 2016-03-17 2021-06-09 Univ Oslo Hf Proteínas de fusión que se dirigen a macrófagos asociados a tumores para tratar el cáncer
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
EP3468581A1 (en) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2017342560B2 (en) 2016-10-14 2022-03-17 Xencor, Inc. IL15/IL15Ralpha heterodimeric Fc-fusion proteins
ES2928718T3 (es) * 2017-04-03 2022-11-22 Hoffmann La Roche Inmunoconjugados de un anticuerpo anti-PD-1 con una IL-2 mutante o con IL-15
KR102408873B1 (ko) 2017-04-05 2022-06-15 에프. 호프만-라 로슈 아게 Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
JP2020529832A (ja) 2017-06-30 2020-10-15 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
EP3665201A4 (en) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
WO2019032663A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. PD-1 AND PD-L1 BINDING AGENTS
JP7327885B2 (ja) 2017-08-09 2023-08-16 オリオンズ バイオサイエンス インコーポレイテッド Ｃｌｅｃ９ａ結合物質およびその使用
AU2018328209A1 (en) 2017-09-05 2020-04-23 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR20200085828A (ko) 2017-11-08 2020-07-15 젠코어 인코포레이티드 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
TW201938196A (zh) * 2018-01-18 2019-10-01 美商南特生物科學股份有限公司 融合蛋白擴展
SG11202007518RA (en) 2018-02-28 2020-09-29 Pfizer Il-15 variants and uses thereof
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CN112437777A (zh) * 2018-04-18 2021-03-02 Xencor股份有限公司 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
WO2019204646A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
MA52289A (fr) * 2018-04-18 2021-02-24 Xencor Inc Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
WO2020077276A2 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
WO2020132646A1 (en) * 2018-12-20 2020-06-25 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
CN114173875A (zh) 2019-03-01 2022-03-11 Xencor股份有限公司 结合enpp3和cd3的异二聚抗体
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
US20220241375A1 (en) * 2019-05-20 2022-08-04 Cytune Pharma Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseases
WO2021034646A1 (en) * 2019-08-17 2021-02-25 Igm Biosciences, Inc. Multimeric bispecific anti-cd123 binding molecules and uses thereof
CN110478474B (zh) * 2019-08-21 2020-06-02 启辰生生物科技(珠海)有限公司 免疫调节剂、疫苗、细胞及应用
CN116574183A (zh) * 2019-08-22 2023-08-11 盛禾(中国)生物制药有限公司 多功能抗体、其制备及其用途
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
RU2753282C2 (ru) 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
KR20220131895A (ko) * 2019-11-21 2022-09-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-pd-1/il-15 면역사이토카인을 이용하여 pd-1을 표적으로 하는 신규한 면역요법
CN110804588B (zh) * 2019-11-22 2020-09-01 启辰生生物科技(珠海)有限公司 用于协同改善t淋巴细胞性质的组合物及其应用
EP3889183A1 (en) * 2020-04-01 2021-10-06 Pierre Fabre Medicament A protein complex comprising an immunocytokine
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
EP4208476A1 (en) * 2020-09-01 2023-07-12 Wuxi Biologics Ireland Limited Long-acting il-15 and uses thereof
AU2021367887A1 (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
JP2023550880A (ja) 2020-10-26 2023-12-06 サイチューン ファーマ 非黒色腫皮膚癌を治療するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト
AU2022232375A1 (en) 2021-03-09 2023-09-21 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5108910A (en) 1989-08-22 1992-04-28 Immunex Corporation DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
PT2112166T (pt) 1998-12-23 2019-01-30 Pfizer Anticorpos monoclonais humanos contra ctla-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
KR100942863B1 (ko) 1999-08-24 2010-02-17 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2003259294A1 (en) 2002-07-30 2004-02-16 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
NZ548325A (en) 2003-12-25 2009-07-31 Kirin Pharma Kk Mutants of anti-CD40 antibody
US7858081B2 (en) 2004-02-27 2010-12-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) IL-15 mutants having agonists/antagonists activity
AU2005259221B2 (en) 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
JP2008521790A (ja) 2004-11-29 2008-06-26 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗菌剤としてのチアゼピンオキサゾリジノン
US7812135B2 (en) 2005-03-25 2010-10-12 Tolerrx, Inc. GITR-binding antibodies
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CA2608474C (en) 2005-05-17 2019-11-12 University Of Connecticut Compositions and methods for immunomodulation in an organism
KR100694508B1 (ko) 2005-05-24 2007-03-13 울산대학교 산학협력단 Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
EA200970477A1 (ru) 2006-11-15 2009-12-30 Медарекс, Инк. Человеческие моноклональные антитела к btla и способы применения
SG183663A1 (en) 2006-12-27 2012-09-27 Univ Emory Compositions and methods for the treatment of infections and tumors
DK2388266T3 (da) 2007-05-11 2014-05-26 Altor Bioscience Corp Fusionsmolekyler og IL-15-varianter
ES2437327T3 (es) 2007-06-18 2014-01-10 Merck Sharp & Dohme B.V. Anticuerpos para el receptor PD-1 humano de muerte programada
CA2691785C (en) 2007-06-27 2017-01-10 Marine Polymer Technologies Inc. Complexes of il-15 and il-15ralpha and uses thereof
SI2851374T1 (sl) 2007-12-14 2017-08-31 Bristol-Myers Squibb Company Vezavne molekule k humanemu ox40 receptorju
JP2011512332A (ja) 2008-02-11 2011-04-21 キュアー テック リミテッド 腫瘍治療のためのモノクローナル抗体
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2009135031A1 (en) 2008-04-30 2009-11-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Substituted il-15
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
EP2342228B1 (en) 2008-09-12 2017-09-06 Oxford University Innovation Limited Pd-1 specific antibodies and uses thereof
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
SI2342226T1 (sl) 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2408818A1 (en) 2009-03-17 2012-01-25 Université de la Méditerranée Btla antibodies and uses thereof
WO2011014438A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
WO2011020047A1 (en) 2009-08-14 2011-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of il-15 to increase thymic output and to treat lymphopenia
RU2595409C2 (ru) 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
AU2011293558B2 (en) 2010-08-23 2014-07-31 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and methods of using the same
KR102070098B1 (ko) 2010-09-21 2020-01-28 알토 바이오사이언스 코포레이션 다량체성 아이엘 15 용해성 융합 분자 및 그의 제조 및 사용 방법
EP2621951A1 (en) 2010-09-29 2013-08-07 Université de Liège Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
HUE039209T2 (hu) 2011-03-31 2018-12-28 Merck Sharp & Dohme Antitestek stabil formulációi emberi programozott halálreceptor PD-1 ellen és ezzel kapcsolatos kezelések
US20140178368A1 (en) 2011-04-19 2014-06-26 Leslie Lynne SHARP Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
RS57324B1 (sr) 2011-04-20 2018-08-31 Medimmune Llc Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
EP2748199B1 (en) 2011-08-23 2019-08-28 Board of Regents, The University of Texas System Anti-ox40 antibodies and methods of using the same
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
JP6359019B2 (ja) * 2012-10-24 2018-07-18 ノバルティス アーゲー ＩＬ−１５Ｒα型、ＩＬ−１５Ｒα型を発現する細胞、ならびにＩＬ−１５ＲαおよびＩＬ−１５／ＩＬ−１５Ｒα複合体の治療上の使用
CA2909576C (en) 2013-04-19 2023-07-18 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
JP2017509319A (ja) 2014-01-15 2017-04-06 カドモン コーポレイション，リミティド ライアビリティ カンパニー 免疫調節剤

Also Published As

Publication number Publication date
CA2919725C (en) 2023-04-18
MX2016001555A (es) 2016-08-03
PT3444271T (pt) 2022-01-05
WO2015018528A1 (en) 2015-02-12
EA031080B1 (ru) 2018-11-30
EP3995507B1 (en) 2023-10-04
KR102364523B1 (ko) 2022-02-18
EP3030575B1 (en) 2018-07-11
KR102564207B1 (ko) 2023-08-10
US20220193199A1 (en) 2022-06-23
AU2014304931B2 (en) 2018-05-10
WO2015018528A8 (en) 2016-04-07
BR112016002614A8 (pt) 2022-11-08
JP6649254B2 (ja) 2020-02-19
US20160175459A1 (en) 2016-06-23
EP3444271A1 (en) 2019-02-20
AU2014304931A9 (en) 2016-06-16
BR112016002614A2 (pt) 2017-09-12
SI3444271T1 (sl) 2022-03-31
HUE064280T2 (hu) 2024-03-28
EP3995507C0 (en) 2023-10-04
CN105612175A (zh) 2016-05-25
HRP20212023T1 (hr) 2022-04-01
ES2902589T3 (es) 2022-03-29
AU2014304931A1 (en) 2016-02-25
EP4269441A3 (en) 2024-01-24
EA201690333A1 (ru) 2016-06-30
CN105612175B (zh) 2023-05-09
KR20220025923A (ko) 2022-03-03
EP4269441A2 (en) 2023-11-01
EP3444271B1 (en) 2021-10-06
DK3444271T3 (da) 2022-01-10
HRP20231437T1 (hr) 2024-02-16
DK3030575T3 (en) 2018-10-22
HRP20181472T1 (hr) 2018-11-02
PL3444271T3 (pl) 2022-03-07
EP3995507A1 (en) 2022-05-11
HUE057598T2 (hu) 2022-05-28
BR112016002614B8 (pt) 2023-10-03
JP2016532693A (ja) 2016-10-20
ES2690046T3 (es) 2018-11-19
PT3030575T (pt) 2018-10-31
JP2020072726A (ja) 2020-05-14
BR112016002614B1 (pt) 2023-10-03
SI3030575T1 (sl) 2018-11-30
ES2963591T3 (es) 2024-04-01
EP3030575A1 (en) 2016-06-15
KR20160042922A (ko) 2016-04-20
PL3030575T3 (pl) 2018-12-31
US11273204B2 (en) 2022-03-15
CA2919725A1 (en) 2015-02-12
JP6951479B2 (ja) 2021-10-20

Similar Documents

Publication Publication Date Title
HRP20181472T1 (hr) Il-15 i il-15r-alpha "sushi domain" modulokini
IL283040A (en) Electronic smoking part and electronic smoking device
HK1220467A1 (zh) 抗- 抗體及其用途
HK1219947A1 (zh) 抑製劑及其用途
HK1214969A1 (zh) 抗- -β抗體及其使用
IL245733A0 (en) aplnr modulators and their uses
GB201317889D0 (en) Product and use
IL240527B (en) Composition of dentures and denture system
GB201305277D0 (en) Novel combination and use
GB201315063D0 (en) Appliances and components therefor
HK1214333A1 (zh) 托架以及使用
IL244214A0 (en) Thienopiperidine derivative and its use
EP2985314A4 (en) CONTACT ELEMENT AND STRUCTURE CONTAINING THE CONTACT ELEMENT
GB2518812B (en) Food Item
GB201309178D0 (en) Enzyme and uses thereof
GB201307989D0 (en) Novel combinations and use
GB201320992D0 (en) Complex and uses thereof
EP2976921A4 (en) ESTIMATION OF INTERFERENCE AND CORRESPONDING DEVICES
GB201311894D0 (en) Conveyor and conveyor structure
ZA201601880B (en) Hetero-transglycosylase and uses thereof
GB201410957D0 (en) Lamp element and lamp
GB201318179D0 (en) Cooking device and method
GB201311696D0 (en) Assembly and methods
GB201310502D0 (en) Device and methods
ES1098430Y (es) Recipiente portador de comida y bebida